BR112022026550A2 - Composição de compostos que modulam o metabolismo celular e métodos de uso - Google Patents

Composição de compostos que modulam o metabolismo celular e métodos de uso

Info

Publication number
BR112022026550A2
BR112022026550A2 BR112022026550A BR112022026550A BR112022026550A2 BR 112022026550 A2 BR112022026550 A2 BR 112022026550A2 BR 112022026550 A BR112022026550 A BR 112022026550A BR 112022026550 A BR112022026550 A BR 112022026550A BR 112022026550 A2 BR112022026550 A2 BR 112022026550A2
Authority
BR
Brazil
Prior art keywords
compounds
composition
methods
cellular metabolism
modulate cellular
Prior art date
Application number
BR112022026550A
Other languages
English (en)
Inventor
KOYUNCU Emre
Hahn Kim
Original Assignee
Crescenta Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescenta Biosciences filed Critical Crescenta Biosciences
Publication of BR112022026550A2 publication Critical patent/BR112022026550A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSIÇÃO DE COMPOSTOS QUE MODULAM O METABOLISMO CELULAR E MÉTODOS DE USO. Uma nova classe de compostos de acordo com a Fórmula I, II ou III, em que W1 ? W4, Z1-Z4, Z1 ? Z5, X, Y, n e R1 ? R8 são conforme definidos nas reivindicações e descrição das modalidades, que se ligam à proteína de ligação a ácidos graxos FABP4 e modulam o metabolismo dos adipócitos para impulsionar a utilização melhorada de glicose, bem como composições farmacêuticas compreendendo a classe de compostos, em combinação com um diluente ou transportador farmaceuticamente aceitável e, opcionalmente, ainda em combinação com um agente terapeuticamente ativo, e o uso destes compostos em medicina e para a preparação de um medicamento no tratamento de distúrbios que atuam na FABP4. Nos exemplos, o anel Z contém Z1-Z4. Em outros exemplos, o anel Z contém Z1-Z5.
BR112022026550A 2020-06-27 2021-06-28 Composição de compostos que modulam o metabolismo celular e métodos de uso BR112022026550A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063045079P 2020-06-27 2020-06-27
PCT/US2021/039470 WO2021263246A1 (en) 2020-06-27 2021-06-28 Novel cell metabolism modulating compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112022026550A2 true BR112022026550A2 (pt) 2023-01-17

Family

ID=79166603

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026550A BR112022026550A2 (pt) 2020-06-27 2021-06-28 Composição de compostos que modulam o metabolismo celular e métodos de uso

Country Status (11)

Country Link
US (2) US12084419B2 (pt)
EP (1) EP4171736A4 (pt)
JP (1) JP2023532888A (pt)
KR (1) KR20230031322A (pt)
CN (1) CN115803085A (pt)
AU (1) AU2021297465A1 (pt)
BR (1) BR112022026550A2 (pt)
CA (1) CA3184282A1 (pt)
IL (1) IL299002A (pt)
MX (1) MX2023000036A (pt)
WO (1) WO2021263246A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230031322A (ko) 2020-06-27 2023-03-07 크레센타 바이오사이언시즈 세포 물질대사를 조정하는 화합물의 조성물 및 사용 방법
CN116761598A (zh) * 2020-07-06 2023-09-15 新月生物科学 Fabp4调节化合物的抗病毒用途
CN114456052B (zh) * 2022-01-25 2023-08-25 哈尔滨工业大学（深圳） 一种不饱和羰基或不饱和亚胺化合物的不对称1,4-加成方法

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3542785A (en) 1967-05-15 1970-11-24 Ciba Geigy Corp 2-hydroxy-4-aryl-quinolines
US3555034A (en) 1968-06-18 1971-01-12 American Home Prod Certain 5,6,7,8-tetrahydro-1,6-naphthyridin-2-ol esters
US3668207A (en) 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
US4009181A (en) 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
DE2431292A1 (de) 1974-06-27 1976-01-15 Schering Ag Neue carbazol-derivate
EP0307077A1 (en) * 1987-07-21 1989-03-15 Merck Frosst Canada Inc. Tetrahydrocarbazoles for the improvement of cyclosporin therapy
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
EP0683890B1 (en) 1991-03-05 2002-04-03 Aradigm Corporation Method and device for correcting the drift offset of a pressure sensor of a flowmeter
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
US6540154B1 (en) 1991-04-24 2003-04-01 Aerogen, Inc. Systems and methods for controlling fluid feed to an aerosol generator
DE69233690T2 (de) 1991-07-02 2008-01-24 Nektar Therapeutics, San Carlos Abgabevorrichtung für nebelförmige Medikamente
FR2682107B1 (fr) 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient Quinoleines 2-substituees pour le traitement des leishmanioses.
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5743250A (en) 1993-01-29 1998-04-28 Aradigm Corporation Insulin delivery enhanced by coached breathing
US5819726A (en) 1993-01-29 1998-10-13 Aradigm Corporation Method for the delivery of aerosolized drugs to the lung for the treatment of respiratory disease
US5994314A (en) 1993-04-07 1999-11-30 Inhale Therapeutic Systems, Inc. Compositions and methods for nucleic acid delivery to the lung
US6228383B1 (en) 1994-03-03 2001-05-08 Gs Development Ab Use of fatty acid esters as bioadhesive substances
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP3706136B2 (ja) 1994-09-21 2005-10-12 ネクター セラピューティクス 乾燥粉末薬剤の分散装置及び方法
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
US6427682B1 (en) 1995-04-05 2002-08-06 Aerogen, Inc. Methods and apparatus for aerosolizing a substance
PT885002E (pt) 1996-03-04 2011-07-14 Massachusetts Inst Technology Materiais e métodos para aumento da internalização celular
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
US6349719B2 (en) 1997-02-24 2002-02-26 Aradigm Corporation Formulation and devices for monitoring the efficacy of the delivery of aerosols
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6257233B1 (en) 1998-06-04 2001-07-10 Inhale Therapeutic Systems Dry powder dispersing apparatus and methods for their use
WO2000015229A1 (en) 1998-09-17 2000-03-23 Bristol-Myers Squibb Company METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION
EP1117378A2 (en) 1998-10-05 2001-07-25 The Penn State Research Foundation Compositions and methods for enhancing receptor-mediated cellular internalization
WO2000047734A1 (en) 1999-02-12 2000-08-17 President And Fellows Of Harvard College Inhibiting formation of atherosclerotic lesions
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
WO2001054694A1 (en) 2000-01-28 2001-08-02 Bristol-Myers Squibb Company Tetrahydropyrimidone inhibitors of fatty acid binding protein and method
US6543443B1 (en) 2000-07-12 2003-04-08 Aerogen, Inc. Methods and devices for nebulizing fluids
CA2422698C (en) 2000-10-16 2009-12-15 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
WO2002040448A1 (en) 2000-11-20 2002-05-23 Bristol-Myers Squibb Company Pyridone derivatives as ap2 inhibitors
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
JP2005527464A (ja) * 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプタＢインドール誘導体
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
AU2004236239A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
PL2037967T3 (pl) * 2006-06-16 2017-07-31 The Trustees Of The University Of Pennsylvania Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego
BRPI0719111A8 (pt) 2006-11-22 2019-01-15 Sumitomo Chemical Co agente para inibir a sinalização de citocinina
ITMI20062254A1 (it) 2006-11-24 2008-05-25 Acraf Uso di un acido metossi-alcanoico dell'indazolo per preparare una composizione farmaceutca
US7722789B2 (en) 2007-11-30 2010-05-25 3M Innovative Properties Company Defoaming method, defoaming device and manufacturing method of transfer mold
CA2743299A1 (en) 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
US20120134998A1 (en) 2009-03-05 2012-05-31 President And Fellows Of Harvard College Secreted ap2 and methods of inhibiting same
US20110077250A1 (en) 2009-06-26 2011-03-31 Ryder Sean Compounds for modulating rna binding proteins and uses therefor
US8470879B2 (en) 2009-11-02 2013-06-25 Life Technologies Corporation Fatty acid inhibitors
WO2012006612A2 (en) 2010-07-09 2012-01-12 President And Fellows Of Harvard College Use of trans-palmitoleate in identifying and treating metabolic disease
EP2593107A1 (en) 2010-07-12 2013-05-22 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
US8889683B2 (en) 2010-09-27 2014-11-18 Merck Sharp & Dohme Corp. Substituted quinoxalines as inhibitors of fatty acid binding protein
JP2014510155A (ja) 2011-04-06 2014-04-24 ザ トラスティーズ オブ プリンストン ユニバーシティ 抗ウイルス組み合わせ治療薬
JP5771750B2 (ja) * 2011-10-28 2015-09-02 チョン クン ダン ファーマシューティカル コーポレーション Ｈｄａｃ阻害剤用のヒドロキサメート誘導体およびこれを含む薬学的組成物
WO2013064465A1 (en) 2011-11-04 2013-05-10 F. Hoffmann-La Roche Ag New aryl-quinoline derivatives
EP2887804B1 (en) * 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators
EP2861574B1 (en) 2012-06-19 2016-04-20 F. Hoffmann-La Roche AG New bicyclic thiophenylamide compounds
US9604904B2 (en) 2012-07-20 2017-03-28 The Research Foundation For The State University Of New York Alpha- and gamma-truxillic acid derivatives and pharmaceutical compositions thereof
WO2014029723A1 (en) 2012-08-24 2014-02-27 F. Hoffmann-La Roche Ag New bicyclicpyridine derivatives
WO2014031986A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2014040938A1 (en) 2012-09-12 2014-03-20 F. Hoffmann-La Roche Ag Non-annulated thiophenylamides as inhibitors of fatty acid binding proteini(fabp) 4 and/or 5
US20150330992A1 (en) 2012-12-12 2015-11-19 The Regents Of The University Of California Rapid discovery and screening of enzyme activity using mass spectrometry
TW201514143A (zh) 2013-03-20 2015-04-16 Hoffmann La Roche 新穎脲衍生物
WO2014177593A1 (en) 2013-04-29 2014-11-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Amorfrutin analogs as ppargamma-modulators
WO2014201326A1 (en) 2013-06-13 2014-12-18 Monsanto Technology Llc Acetyl-coa carboxylase modulators
US10207995B2 (en) 2013-06-13 2019-02-19 Monsanto Technology Llc Acetyl CoA carboxylase modulators
US9938222B2 (en) 2014-09-09 2018-04-10 Bristol-Myers Squibb Company Cyclopropanecarboxylic acid GPR120 modulators
EP3209794A1 (en) 2014-10-22 2017-08-30 Katholieke Universiteit Leuven KU Leuven Research & Development Modulating adipose tissue and adipogenesis
US9968616B2 (en) * 2014-10-25 2018-05-15 The Chinese University Of Hong Kong Discovery of FDA-approved drugs as inhibitors of fatty acid binding protein 4 using molecular docking screening
UY36838A (es) 2015-08-03 2017-01-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen
WO2017034986A1 (en) 2015-08-21 2017-03-02 University Of Kansas Human tlr8-selective agonists
DK3452465T3 (da) 2016-05-04 2021-02-08 Genoscience Pharma Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
EP3246028A1 (en) 2016-05-18 2017-11-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline compounds for increasing insuline release
US11229624B2 (en) 2016-10-25 2022-01-25 Ticure Ltd. FABP4 as a therapeutic target in skin diseases
US20180357361A1 (en) 2017-06-13 2018-12-13 Feliks Frenkel Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy
WO2019018785A2 (en) 2017-07-20 2019-01-24 University Of Florida Research Foundation, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
KR20230031322A (ko) 2020-06-27 2023-03-07 크레센타 바이오사이언시즈 세포 물질대사를 조정하는 화합물의 조성물 및 사용 방법

Also Published As

Publication number Publication date
US20220002243A1 (en) 2022-01-06
AU2021297465A1 (en) 2023-03-02
EP4171736A1 (en) 2023-05-03
MX2023000036A (es) 2023-02-01
IL299002A (en) 2023-02-01
US12084419B2 (en) 2024-09-10
WO2021263246A1 (en) 2021-12-30
JP2023532888A (ja) 2023-08-01
EP4171736A4 (en) 2024-07-03
CA3184282A1 (en) 2021-12-30
US20230331673A1 (en) 2023-10-19
KR20230031322A (ko) 2023-03-07
CN115803085A (zh) 2023-03-14

Similar Documents

Publication Publication Date Title
BR112022026550A2 (pt) Composição de compostos que modulam o metabolismo celular e métodos de uso
Chen et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update)
BR112022015002A2 (pt) Ligante de il-7r-alfa/gama/c, composto, composição farmacêutica, método para tratar uma doença em um paciente e ácido nucleico
BR112023024646A2 (pt) Composto tetacíclico fundido, método de preparação do mesmo e aplicação do mesmo na medicina
BR112022008750A2 (pt) Composto de ligação de receptor duplo, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico
AU599086B2 (en) Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
Yang et al. PGC-1 mediates the regulation of metformin in muscle irisin expression and function
SI1644009T1 (en) COMPOSITION TO INCREASE TELECOMMUNICATION ACTIVITY AND TREATMENT OF HIV INFECTION
Shree et al. Human adipose tissue mesenchymal stem cells as a novel treatment modality for correcting obesity induced metabolic dysregulation
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BR112022013009A2 (pt) Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
BRPI0507895A (pt) composição para o tratamento de insuficiências venosas crÈnicas, compreendendo um extrato de folhas de videira-vermelha e um agente antiinflamatório
BR112014011981A2 (pt) formulações farmacêuticas
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
BR112022014245A2 (pt) Compostos de modulação do metabolismo celular inovadores e usos dos mesmos
BR112014003981A2 (pt) compostos de pirimido-piridazinona e seu uso
EP4058022A1 (en) (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds
AR008387A1 (es) Nuevas 5-fenoxialquil-tiazolidin-2,4-dionas, procedimientos para obtenerlas, nuevos compuestos intermedios de estos procedimientos ycomposiciones farmaceuticas que contienen las nuevas 5-fenoxialquil-tiazolidin- 2,4-dionas
IL292770A (en) Formulations and dosages of polyethylene glycol-modified oricase